Latest news

• GSK’s Nucala gets boost with self-administration approval

  The drug earned £152m ($193m) in Q1 this year (up 41% on the same period a year earlier) but is also facing competition from other IL-5 inhibitors including AstraZeneca’s  ... Another significant challenger in the market is Sanofi's Dupixent, a dual

• Sanofi's Dupixent gains asthma approval in Europe

  The dual IL-4 and IL-13 inhibitor has just gained approval for the new use in the European Union, and the partners are amassing data which shows it can alleviate

• CHMP backs Lynparza in breast cancer, Dupixent in asthma

  For Sanofi and its Dupixent (dupilumab) partner Regeneron, approval for the IL-4 and IL-13 inhibitor as an add-on maintenance treatment for severe asthma is also viewed as a ... AbbVie and Boehringer Ingelheim’s IL-23 inhibitor Skyrizi (risankizumab)

• AZ, Amgen’s first-in-class asthma drug gets breakthrough status

  Drugs like Fasenra and GlaxoSmithKline’s rival IL-5 inhibitor Nucala (mepolizumab) have emerged as an important treatment option for people with severe asthma characterised by high levels of eosinophils. ... Regeneron’s new candidate Dupixent

• GSK sells eczema and psoriasis drug to Dermavant for £250m

  The cut included IL-6 inhibitor sirukumab for rheumatoid arthritis, which left tapinarof as the lead candidate in its immuno-inflammation programme. ... Meanwhile, in atopic dermatitis, Regeneron and Sanofi’s IL4/IL-13 inhibitor Dupixent (dupilumab)